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Abstract
Background: The clinical application of TRAIL receptor agonists as a novel cancer therapy has been tempered by
heterogeneity in tumour responses. This is illustrated in breast cancer, where TRAIL is cytotoxic in cell lines of
mesenchymal origin but refractory in lines with an epithelial-like phenotype. However, it is now evident that
intra-tumour heterogeneity includes a minority subpopulation of tumour-initiating stem/progenitor-like cells (CSCs)
that possess mesenchymal characteristics. We hypothesised therefore that TRAIL may target these phenotypically
distinct CSC-like cells that are common to most - if not all - breast cancers, thus impacting on the source of
malignancy in a much broader range of breast tumour subtypes than previously envisaged.
Methods: We used colony formation, tumoursphere, flow cytometry and xenograft tumour initiation assays to observe
the TRAIL sensitivity of CSC-like cells in a panel of two mesenchymal-like (TRAIL-sensitive) and four epithelial-like
(TRAIL-resistant) breast cancer cell lines. Subcellular levels of the endogenous TRAIL inhibitor, cFLIP, were determined
by western blot and immunofluorescence microscopy. The effect of the subcellular redistribution of cFLIP on TRAIL
sensitivity and Wnt signalling was determined using cFLIP localisation mutants and the TOPFlash reporter assay
respectively.
Results: TRAIL universally suppressed the clonal expansion of stem/progenitors in all six of the breast cancer
cell lines tested, irrespective of their phenotype or overall sensitivity to TRAIL. A concomitant reduction in
tumour initiation was confirmed in the TRAIL-resistant epithelial cell line, MCF-7, following serial dilution
xenotransplantation. Furthermore TRAIL sensitivity of breast CSCs was inversely proportional to the relative
cytoplasmic levels of cFLIP while overexpression of cFLIP in the cytosol using subcellular localization mutants
of cFLIP protected these cells from cytotoxicity. The accumulation of nuclear cFLIP on the other hand did not
influence TRAIL cytotoxicity but instead promoted Wnt-dependent signalling.
Conclusion: These data propose a novel role for TRAIL as a selective CSC agent with a broad specificity for
both epithelial and mesenchymal breast tumour subtypes. Furthermore we identify a dual role for cFLIP in
the maintenance of breast CSC viability, dependent upon its subcellular distribution.
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Background
Breast tumours have intrinsic heterogeneity. Breast can-
cer cells with stem-like properties make up only a small
fraction of a tumour, but owing to their role as instiga-
tors of tumourigenesis, are believed to impart the major-
ity of the malignant phenotype [1]. The clinical
implication of this cellular heterogeneity is that the effi-
cacy of any therapeutic strategy should be measured by
its ability to target stem-like cell sub-populations and
thus improve upon long term tumour responses. An
additional problem however is that breast cancer stem
cells (bCSCs) are resistant to radiotherapy and chemo-
therapy, and thus by targeting only non-bCSCs, many
existing therapeutic regimens may actually increase the
proportion of bCSCs within a tumour [2–4]. To date,
only a few drugs have been shown to be capable of tar-
geting bCSCs [5, 6]. Therefore there is a clear need to
identify effective therapeutics capable of targeting this
minority population of highly malignant cells.
Tumour Necrosis Factor Alpha Receptor Apoptosis
Inducing Ligand (TRAIL) is a soluble cytokine manufac-
tured by cells of the immune system. TRAIL functions
to activate the extrinsic apoptosis pathway in target cells
to induce caspase-mediated cell death. This pathway can
be inhibited within the cytoplasm by the endogenous
Cellular FLICE-Like Inhibitory Protein (cFLIP) that acts
by competing with caspase 8 for recruitment to the
death inducing signalling complex, formed in response
to TRAIL- mediated trimerization of its cognate recep-
tors at the cell surface [7]. Initial reports of the ability of
TRAIL to target and induce apoptosis preferentially in
cancerous cells led ultimately to the production of clin-
ically approved TRAIL agonists for a number of cancers
including lymphoma and lung cancer [8–10]. How-
ever, despite their initial promise in pre-clinical stud-
ies, overall efficacy of TRAIL agonists in a variety of
cancer types has been limited to a minority of partial
or complete responders culminating in a limited clin-
ical uptake [10–18]. Thus a better understanding of
how and why tumour cells respond differently to
TRAIL is called for in order to realise its potential as
a therapeutic.
Pre-clinical studies have shown that mesenchymal-like
breast cancer cell lines are sensitive to the cytotoxic ef-
fects of TRAIL whereas epithelial-like lines are TRAIL-
resistant [19]. The cause of this correlation has not yet
been explained. With the discovery that at least a pro-
portion of bCSCs commonly exhibit mesenchymal char-
acteristics [20–22], we hypothesised that TRAIL may be
able to target the bCSC-like population in a broad range
of tumour subtypes. We have shown previously that the
stem-like cells of four breast cancer cell lines can be sen-
sitised to TRAIL by inhibition of cFLIP, resulting in de-
creased tumourigenicity in vivo [23]. This implied that
cFLIP may have a key role in determining the sensitivity
of bCSCs to TRAIL-induced cytotoxicity. However, due
to its homology to the pro-apoptotic caspase 8, it has
not yet been possible to develop a selective small mol-
ecule inhibitor of cFLIP. Any targeted combination ther-
apy is therefore a long way from the clinic. In contrast,
given that TRAIL is available now; the ability to identify
those patients most likely to respond favourably to
TRAIL as a single agent could lead to its more rapid
clinical use. To this end we set out to investigate the
susceptibility of bCSCs to TRAIL and the underlying
mechanisms which determine TRAIL-susceptibility in
breast cancer cell lines.
Here we demonstrate that TRAIL alone was able to
inhibit the clonal expansion of all six breast cancer cell
lines tested, even those regarded previously as refractory
to TRAIL cytotoxicity. The sensitivity of stem/progeni-
tor-like cells (here referred to as bCSCs) to TRAIL was a
direct consequence of the sub-cellular re-distribution of
cFLIP from the cytoplasm, with an inverse correlation
between the level of cytosolic cFLIP and TRAIL suscep-
tibility. Consequently, nuclear cFLIP was not able to
protect from TRAIL but instead promoted the Wnt sig-
nalling pathway, providing a potential explanation for
the previously unexplained association between TRAIL-
sensitivity and the mesenchymal phenotype.
These data suggest that the effect of TRAIL may not
be limited to mesenchymal subtypes of breast cancer
and indicates a potentially beneficial role for TRAIL as a
selective CSC agent.
Methods
All experiments were performed with the approval of
the University of Cardiff, School of Biosciences Ethics
Committee and animal work was performed in accord-
ance with the Home Office Animals (Scientific Proce-
dures) Act 1986 under project licence 30/2849.
Constructs
The pcDNA3.1cFLIPL overexpression vector, containing
the full length coding sequence of the long form of hu-
man c-FLIP (accession number NM_003879) was a kind
gift from Dr. Naito (Institute of Molecular and Cellular
Biosciences, Tokyo University, Japan). The Mission
cFLIPSh vector was a kind gift from Dr. Ladislav Andera
(Institute of Molecular Genetics, Prague, Czech Repub-
lic). The FOPFlash and TOPFlash reporter plasmids
were kind gifts from Dr. Ken Ewan, Cardiff University
School of Biosciences.
Site directed mutagenesis
Site directed mutagenesis was performed on the
pcDNA3.1cFLIPL construct, using the QuickChange kit
(Stratagene) according to the manufacturer’s instructions
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to introduce the following mutations; LL439AA and
RKR435LIL into the nuclear export and localisation se-
quences respectively [24]. The following mutagenic
primers were used:
NES: LL439AA
3′-CTGTTCTTTCTTTTGCGGGTCGGCGCCTAGA
AGTGTAACTTGAGTTACC-5′
5′-GACAAGAAAGAAAACGCCCAGCCGCGGATC
TTCACATTGAACTCAATGG-3′
NLS: RKR435LIL
3′-GGTCTTTGACTCTGTTCTTGATTATGAGGGT
GAGGACCTAGAAGTGTCG-5′
5′-CCAGAAACTGAGACAAGAACTAATACTCCCA
CTCCTGGATCTTCACAGC-3′
Cell lines and reagents
The human breast cancer cell lines were obtained
from ATCC (MDA-MB-231ER-HER2- SKBR3HER2+
BT474 ER+HER2+) and CLS (MDA-MB-468 ER-HER2-
MDA-MB-436 ER-HER2-) except the MCF-7 line which
was a kind gift from Dr Julia Gee, Cardiff University. All
cell lines were maintained in RPMI 1640 medium (Invitro-
gen) supplemented with 10 % foetal bovine serum (FBS)
(Invitrogen), and 1 % penicillin-streptomycin and L-
glutamine mix (Invitrogen). Cells were maintained at 37 °C
in 5 % CO2.
Recombinant soluble human TRAIL was purchased as
super-killer TRAIL from Enzo Life Sciences. Unless other-
wise stated , cells were treated with 20 ng/ml TRAIL for
18 h before subsequent assays. The pan-caspase inhibitor
Z-Vad-Fmk was purchased from R and D systems and
used at a concentration of 20uM. Cells were pre-treated
with caspase inhibitor for 1 h prior to treatment with
TRAIL. Leptomycin B was purchased from Sigma and
used at a concentration of 0.1 ng/ml.
Overexpression and inhibition of cFLIP in cell lines
Cells were transformed with pcDNA3.1cFLIPL overex-
pression constructs using lipofectamine 3000 (Invitro-
gen) according to the manufacturer’s instructions and
maintained under antibiotic selection.
In order to inhibit cFLIP, cells were transduced with
lentivirus containing shRNA and maintained under anti-
biotic selection:
cFLIP shRNA Fwd:
5′GATCTCCGGGGATAAATCTGATGTGTCCTCA
TTACTCGAGTAATGAGGACACATCAGATTTATC
CTTTTTA-3′
cFLIP shRNA Rev:
5′AGCTTAAAAAGGATAAATCTGATGTGTCCTC
ATTACTCGAGTAATGAGGACACATCAGATTTATC
CCCGGA-3′
Alternatively, cells were transformed with siRNA using
lipofectamine RNAiMax (Invitrogen) according to the
manufacturer’s instructions, and cultured in the pres-
ence of lipid complexes for 48 h prior to the subsequent
assay. The following siRNA oligos were custom designed
and purchased from Invitrogen:
cFLIP 1: 5′-GGAUAAAUCUGAUGUGUCCUCAU
UA-3′,
cFLIP 2: 5′-GAGUGAGGCGAUUUGACCUGCUC
AA-3′,
Scrambled control: 5′-GGACUAAUAGUUGUGCUC
CAAUUUA-3′.
Cell viability assay
Cells to be analysed were cultured in a 96-well plate for-
mat. On the day of analysis, 20 μl of Cell Titre Blue re-
agent (Promega) was added to each well containing
100 μl media. The plate was incubated for 1–4 h at 37 °
C 5 % CO2, before fluorescence was measured at 560/
590 nm using a FLUOstar Optima plate reader (BMG
Labtech, Offenberg, Germany).
Tumoursphere formation assay
Tumoursphere assays were carried out in non-adherent
conditions in a serum-free epithelial growth medium
(MEBM, Lonza), supplemented with B27 (Invitrogen),
20 ng/ml EGF (Sigma), 5 μg/ml Insulin (Sigma), and
25 μg/ml hydrocortisone (Sigma). Cells were plated in
ultra-low attachment plates (Costar, Corning) at a dens-
ity of 5000 cells/ml. After 7 days tumourspheres were
counted, then collected by gentle centrifugation
(1100 rpm), dissociated in 0.05 % trypsin, 0.25 % EDTA
(Invitrogen) and re-seeded at 5000 cells/ml for subse-
quent passages [25, 26].
Colony forming assay
Cells were seeded at a density of 185 cells/well in a 12-
well plate format, so that cells were 50 per square cm,
and cultured for 10 days [27, 28]. To stain colonies, cul-
ture medium was removed and well surface was washed
once with PBS. Crystal violet/ethanol mixture was ap-
plied to wells and incubated for 15 mins at room
temperature. Solution was removed and wells were
rinsed twice with PBS. Colonies containing approxi-
mately 32 or more cells (having undergone 5 or more di-
visions) were counted using a GelCount platereader and
software (Oxford Optronix) set to count colonies of size
100-1000 μm.
Tumour initiation in vivo
Serial dilutions of untreated and TRAIL-treated cells
were prepared in 50 % Matrigel (BD Biosciences). The
cell/Matrigel mix was injected above the lymph nodes of
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the fourth inguinal mammary fat pad with a Hamilton
or insulin needle syringe (BD Micro-Fine). FoxN1Nu/Nu
mice were used for all xenograft studies (Harlan Life Sci-
ences, UK). Mice were administered oestrogen in the
water during the course of the experiment at a concen-
tration of 10 μg/ml. Mice were examined for tumour
growth twice weekly by palpation. Tumours were mea-
sured using callipers and tumour volume was measured
by the calculation; (tumour width2) x tumour length/2.
Mice were culled when the entire control group devel-
oped tumours at least 5 mm in diameter, and mammary
glands, lungs and livers of mice were fixed in formalin
for histological analysis.
Luciferase reporter assay
Following 48 h transfection with TOPFlash, FOPFlash
and LacZ reporter plasmids, cells were lysed using 50 μl
Passive lysis buffer (Promega) for 30 mins. To each of
two white-sided 96-well plates (Costar, Corning), 30 μl
of cell lysate was transferred. To assay for LacZ activity,
to one plate 30 μl Beta-Glo reagent (Promega) was
added and incubated at room temperature with gentle
shaking for 20 mins before measuring luminescence out-
put. To the second plate, 30 μl of Bright-Glo reagent
(Promega) was added to assay for TOPFlash reporter ac-
tivity and the luminescence measured immediately using
a FLUOstar Optima plate reader (BMG labtech, Offen-
berg, Germany). TOPFlash reporter activity was normal-
ised to LacZ activity to control for transfection
efficiency.
qRT-PCR analysis
RNA extraction was performed using the Qiagen
RNEasy kit according to the manufacturer’s instructions.
Resulting RNA was incubated with DNase (Amplicon)
for 15 mins before inactivation. RNA concentration was
determined using a Nanodrop (GE Healthcare, UK).
cDNA was synthesised using MMLV reverse transcript-
ase (Promega) according to manufacturer’s instructions.
Primers were custom designed across exon boundaries
using the Primer3 web-based program (http://primer3.u-
t.ee/) and purchased from Sigma. cFLIP: Forward: 5′-
TGATGGCAGAGATTGGTGAG-3′, and reverse 5′-
GATTTAGACCAACGGGGTCT-3′. Axin 2: Forward,
5′-AGTGTGAGGTCCACGGAAAC-3′ and reverse 5′-
TGGCTGGTGCAAAGACATAG-3′. qPCR was per-
formed using GoTaq polymerase (Promega) and Real-
Time PCR machine using StepOne software (Applied
Biosystems).
Western blotting
Total cellular or cytoplasmic proteins were extracted
from cultured cells and analysed by Western blotting.
cFLIP antibodies used were purchased from Santa Cruz
(5D8) and R and D systems (AF821). Beta Catenin anti-
body was purchased from BD Biosciences (610154). To
quantitate Western data blots were digitally scanned and
the pixel intensity of each band quantified relative to its
protein loading control (alpha tubulin or lamin A/C) by
densitometry using the program ImageJ (http://imagej.-
nih.gov/ij/).
Immunofluorescence
Cells from culture were seeded onto glass coverslips
placed in wells of a 48-well culture plate, and allowed to
adhere. Cells on coverslips were fixed in 4 % formalin
for 15 mins followed by 3 × 5 min washes in PBS, then
blocked for 1 h in 10 % normal goat serum (Dako) in
PBS with 0.5 % triton-X-100 (Sigma). Cells were then in-
cubated in the primary antibody diluted 1:100, overnight
at 4 °C. Following 3 × 5 min washes in PBS, cells were
incubated in fluorescence-conjugated secondary anti-
bodies (Alexa Fluors, Invitrogen) diluted 1:400 in 10 %
normal goat serum (Dako) and containing DAPI nuclear
stain (Invitrogen) for 1 h. Coverslips were then washed 3
× 5 mins in PBS and mounted in Mowiol solution
(Sigma). Cells were visualised on a Leica confocal micro-
scope. cFLIP antibody used for fluorescence was pur-
chased from Cell Signalling.
Flow cytometry
Cells to be analysed were trypsinised, washed and incu-
bated for 1 h in antibody diluted 1:100 in PBS. Flow cy-
tometry was performed on an Accuri Flow Cytometer
(BD Biosciences) and analysis of results was performed
using a FlowJo software package. APC-conjugated CD44
antibody was purchased from BD Pharmingen, PE-
conjugated ALDH1 antibody was purchased from
Stratech.
Statistical analysis
Throughout the article, data are represented as mean
and error bars as standard error of a minimum of three
independent experiments, unless otherwise stated. Stat-
istical significance was determined using a student’s T-
test for two-paired samples. Pearson’s correlation coeffi-
cient was used to determine whether data was linearly
associated. L-Calc software was used to estimate stem
cell number from serial dilutions of tumour xenografts
(http://www.stemcell.com/en/Products/All-Products/
LCalc-Software.aspx)
Results
TRAIL targets breast cancer stem/progenitor-like cells
Breast cancer cell lines with a mesenchymal-like morph-
ology are relatively more susceptible to the pro-
apoptotic effects of TRAIL than their epithelial-like
counterparts [19]. On the basis that cancer stem / early
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progenitor cells (CSCs) have been associated with mes-
enchymal characteristics we wished to test the hypoth-
esis that TRAIL might preferentially target bCSCs
within all breast cancer subtypes, including otherwise re-
sistant epithelial-like cell lines. We used a panel of six
breast cancer cell lines that had been reported previously
to exhibit different responses to TRAIL-mediated cyto-
toxicity [19]. We first confirmed that in adherent cul-
ture, only those breast cancer cell lines with a
mesenchymal-like phenotype (MDA-MB-231 and MDA-
MB-436) were sensitive to TRAIL, whereas epithelial-
like cell lines (MCF-7, BT474, SKBR3 and MDA-MB-
468) were TRAIL-resistant (Fig. 1a).
Colony formation assays were then performed to as-
sess the ability of the minority stem/progenitor cell
population within each cell line to expand to form col-
onies in adherent culture following TRAIL treatment
[27, 28]. Each of the six breast cancer cell lines were
plated at low density in the presence or absence of
TRAIL and colonies allowed to form over a ten day
period. Only those colonies containing 32 or more cells
(having undergone 5 or more divisions) were counted
Fig. 1 Breast Cancer Stem/progenitors are TRAIL-Sensitive: (a) Cell Titre Blue assay performed on 6 cell lines treated for 18 h with 20 ng/ml TRAIL
(T) or vehicle control (−). The viability of each line is shown as a percentage of its untreated control. (b) Colony-Forming Assay performed on 6
cell lines seeded at low density in the presence or absence of 20 ng/ml TRAIL for 10 days. The proportion of colonies formed is shown as a percent-
age of its untreated control. (c) Tumoursphere Assay performed on each cell line in the presence or absence of 20 ng/ml TRAIL. The proportion of
tumourspheres for each cell line is shown as a percentage of its untreated control. (d) MCF-7 and MDA-MB-231 cell lines were treated for 18 h in the
presence or absence of 20 ng/ml TRAIL, then subjected to tumoursphere Assay performed in the absence of TRAIL. The percentage of tumourspheres
is shown relative to the number of cells seeded (e) Tumour Initiation in vivo. MCF-7 cells were pre-treated with 20 ng/ml TRAIL for 18 h then implanted
into the mammary fat pad of nude mice at serial dilutions. The number of tumours formed relative to transplants was determined by palpation and
confirmed by histological analysis at the end of the experiment. An estimation of the proportion of viable stem cells was performed using L-Calc
software however a statistically significant comparison was not possible as control data was inconsistent with the model (f) Flow Cytometry of MCF-7
cells treated with TRAIL for 18 h and stained with fluorescence-conjugated antibodies to CD44 and ALDH. The percentage of marker-positive cells is
shown relative to the number of cells analysed (*p < 0.05, paired t-test, error bars = SEM; all graphs represent means of 3 independent experiments)
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[28]. TRAIL inhibited colony formation in all six breast
cancer cell lines tested (Fig. 1b and Additional file 1: Fig-
ure S1A), indicating that the small minority of cells re-
sponsible for this clonal expansion were selectively
targeted even in a cell line otherwise refractory to
TRAIL. Furthermore colony formation could be rescued
in the presence of a pan-caspase inhibitor confirming
that TRAIL mediated this effect through caspase-
dependent cytotoxicity (Additional file 1: Figure S1B).
To determine if TRAIL also suppressed the stem-like
traits of self-renewal and anoikis resistance, CSC proper-
ties associated with tumour initiation, each of the cell
lines were incubated in the presence/absence of TRAIL
in non-adherent tumoursphere conditions. Tumour-
sphere formation was suppressed by TRAIL in four out
of six of the breast cancer cell lines tested, including two
of the resistant epithelial-like cell lines, MCF-7 and
MDA-MB-468 (Fig. 1c and Additional file 1: Figure S1C
and D). To confirm that the observed reduction in
tumoursphere number was due to a loss of the stem/
progenitor compartment, rather than a loss of subse-
quent clonal expansion, MCF-7 and MDA-MB-231 cells
were pre-treated with TRAIL in adherent conditions,
prior to seeding of the surviving cells in tumoursphere
conditions without TRAIL. MCF-7 tumoursphere- form-
ing cells (TFCs) were significantly more TRAIL-sensitive
than the total MCF-7 population whereas TFCs of the
TRAIL sensitive MDA-MB-231 line were equally as sen-
sitive to TRAIL as the total cell population (Fig. 1d).
In the two cell lines that exhibited no relative loss in
TFC numbers (SKBR3 and BT474: Fig. 1c), continuous
TRAIL treatment resulted in a significant reduction in
sphere size, confirming our findings in colony forming
assays that TRAIL suppressed the clonal expansion of
early stem/progenitors (Additional file 1: Figure S1E).
These data combined suggest that although TRAIL
may not target stem-like cells directly in all breast
tumour lines, the range of tumour types in which
bCSCs are susceptible extends to epithelial-like as
well as mesenchymal-like cell lines. Furthermore all
cell lines tested exhibited attenuated clonal expansion
of stem/progenitors together, supporting our hypoth-
esis that TRAIL treatment may target tumour initi-
ation and/or propagation in a broader range of
tumour subtypes than assumed previously. To deter-
mine the effect of TRAIL on tumour-initiation dir-
ectly we performed limiting dilution transplantation
of one of the most TRAIL-resistant cell lines. MCF-7
cells were treated with TRAIL in vitro for 24 h then
viable cells transplanted into the mammary fat pad of
mice in the absence of TRAIL. Pre-treatment with
TRAIL reduced the number of tumours formed even
though equal numbers of viable cells were trans-
planted compared to untreated controls (Fig. 1e).
The cell surface marker profiles of CD44+or ALDH+
have been shown previously to enrich for stem/progeni-
tor-like cells with increased capacity for tumour initiation
[1, 29]. More recently these marker profiles have been
shown to identify two separate subpopulations of stem-
like cells [22]. We assessed the ability of TRAIL to target
cells with these CSC markers. Treatment of MCF-7 cells
with 20 ng/ml TRAIL for 18 h selectively reduced the
CD44+ population, whereas TRAIL had no significant ef-
fect on ALDH+ cells (Fig. 1f, and Additional file 1: Figure
S1F). As CD44+ is thought to identify cells of a more
mesenchymal-like nature compared to ALDH [22], our
findings are consistent with the established specificity of
TRAIL for cells with mesenchymal-like traits [19].
TRAIL susceptibility correlates with reduced levels of
cytoplasmic cFLIP
While these results indicate a broader TRAIL-specificity
of breast cancer stem/progenitors than had been de-
scribed previously for the total cell populations, the
underlying cause of this differential sensitivity to TRAIL
is unknown. We have shown previously that inhibition
of the “long” isoform of cFLIP sensitises tumoursphere-
forming cells to TRAIL [23]. This suggests that the
TRAIL-susceptibility of cells with bCSC-like traits is de-
termined, at least in part, by the apoptosis inhibitor
cFLIP. Therefore one potential explanation for the ob-
served differences in TRAIL susceptibility between
breast cancer cells could be that TRAIL-sensitive cells
may contain lower levels of cFLIP. To test this possibil-
ity, protein was extracted from breast cancer cell lines
grown in adherent culture and from cells suspended in
tumoursphere culture for two days to enrich for cells
with a stem or progenitor-like phenotype [30]. We ob-
served no direct correlation between the total protein
levels of cFLIP and TRAIL-susceptibility in either the
adherent (total) populations or the anoikis-resistant
(bCSC-enriched) cells, suggesting that total cFLIP levels
do not determine TRAIL-susceptibility (Fig. 2a and b
and Additional file 1: Figure S2A and B).
In order to inhibit the extrinsic apoptosis pathway,
cFLIP must be available in the cytoplasmic compart-
ment of the cell to complex with DISC components
and thus interfere with caspase 8 recruitment [7].
Previous studies in lung carcinoma cell lines have
found cFLIP (specifically the long form) is able to
translocate to the nucleus where it was shown to pro-
mote Wnt target gene expression [24]. Given the pre-
viously reported association between mesenchymal-
like cells and elevated Wnt signalling [31] we inferred
that sub-cellular compartmentalisation of cFLIP, ra-
ther than total protein levels, might influence TRAIL-
sensitivity at the cellular level; more specifically that
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Fig. 2 Cytoplasmic cFLIP Levels Correlate with TRAIL Susceptibility (a) Representative western blots for cFLIPLong performed on total protein
extracts of cell lines MCF-7, MDA-MB-231 (MD231), MDA-MB-468 (MD468) and MDA-MB-436 (MD436). Loading control = α-tubulin. (b) Western
blots for cFLIPLong performed on total protein extracts of cell lines grown in adherent culture (Line) and non-adherent tumoursphere conditions
(Spheres). Loading control = α-tubulin. (c) Western blots for cFLIPLong performed on cytoplasmic protein extracts of cell lines. Loading control
= α-tubulin. (d) Western blots for cFLIPLong performed on cytoplasmic protein extracts of cell lines grown in adherent (Line) or tumoursphere
(Spheres) conditions. Loading control = α-tubulin. (e) Comparison of relative cytoplasmic cFLIP levels and relative TRAIL-susceptibility (normalised
to that of the MCF-7 line). SKBR3 and MDA-MB-468 datapoints overlap (*SKBR3 n = 2) (r = −0.98 > −0.99, Pearson’s correlation co-efficient).
(f) Comparison of relative cytoplasmic cFLIP levels and relative TRAIL-susceptibility in bCSC-enriched non-adherent tumourspheres (normalised to
that of their bulk cell line) (r = −0.96 < −0.95, Pearson correlation co-efficient). (g) Immunofluorescence of MCF-7 and MDA-MB-231 cells for cFLIP (cFLIP
= grey, DAPI = red) (h) Immunofluorescence of anoikis-resistant MCF-7 cells before and after TRAIL-treatment (cFLIP = grey and DAPI = red). All western
blots and quantitative data are representative of 3 independent experiments. Quantitation of the mean relative levels of cFLIP in experiments (a-d) are
presented in Additional file 1: Figure S2
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cytoplasmic cFLIP may be reduced in TRAIL-sensitive
cells.
To investigate cytoplasmic levels of cFLIP, nuclear-
free cytoplasmic protein fractions were extracted
from both the total adherent cell populations and
anoikis-resistant populations (bCSC enriched), and
levels of cFLIP determined by densitometry of im-
munoblots. Cytoplasmic cFLIP was reduced in both
the MDA-MB-231 and MDA-MB-436 TRAIL-
sensitive cell lines but not in TRAIL-resistant MDA-
MB-468 cells relative to the MCF-7 cell line (Fig. 2c
and Additional file 1: Figure S2C). Cytoplasmic
cFLIP was also reduced in TRAIL-sensitive tumour-
spheres (MCF-7, MDA-MB-231 and MDA-MB-468)
but unchanged in TRAIL-resistant tumourspheres of
SKBR3 cells (Fig. 2d and Additional file 1: Figure
S2D). Thus in both bulk-tumor cells and enriched
stem/progenitor populations the relative levels of
cytoplasmic cFLIP significantly correlated with
TRAIL susceptibility (Fig. 2e and f ).
To confirm the relative subcellular distribution of
cFLIP, cells were immunostained for cFLIP in situ and
examined by confocal microscopy in two representative
cell lines with differential TRAIL sensitivity. In the
TRAIL-sensitive MDA-MB-231 line, cFLIP localised to
the nuclear and peri-nuclear compartments, whereas in
the TRAIL-resistant MCF-7 line cFLIP staining was
punctate and primarily cytoplasmic (Fig. 2g). Analysis of
the distribution of staining through the z-plane further
confirmed the partial overlap between nuclear content
(DAPI) and nuclear/peri-nuclear cFLIP in MDA-MB-
231 cells, in contrast to the exclusive distribution of
cFLIP and DAPI in MCF-7 cells (Additional file 1: Figure
S2E). The anoikis-resistant subpopulation of MCF-7
(tumoursphere) cells, previously demonstrated to be sen-
sitive to TRAIL (Fig. 1c), were also analysed by immuno-
fluorescence. In contrast to the total cell population
which exhibited cytoplasmic cFLIP (Fig. 2g), anoikis-
resistant cells exhibited nuclear staining and thus a rela-
tive decrease in cytoplasmic cFLIP (Fig. 2h, TRAIL-
untreated). As expected, treatment with TRAIL reduced
tumoursphere number by approximately fifty percent as
shown previously (Fig. 1c). The remaining TRAIL-
resistant treated (and therefore resistant) cells exhibited
a marked elevation in cytoplasmic cFLIP (Fig. 2h,
TRAIL-treated). Analysis of the distribution of staining
through the z-plane also revealed an overlap between
DAPI and cFLIP in anoikis-resistant MCF-7 cells
whereas little overlap was apparent in the remaining
TRAIL-treated (and therefore TRAIL-resistant) MCF-7
anoikis-resistant cells (Additional file 1: Figure S2F).
Taken together, these data are consistent with the hy-
pothesis that cytoplasmic cFLIP is reduced in TRAIL-
sensitive cells.
Cytoplasmic cFLIP protects cancer stem/progenitors from
TRAIL induced cytotoxicity
To investigate the functional consequences of cytoplas-
mic redistribution of c-FLIP on TRAIL- sensitivity, sub-
cellular localisation mutants of cFLIP were generated ac-
cording to Katayama et al. 2010 [24]. By mutating the
nuclear localisation and export sequences of cFLIP, it
was possible to generate cFLIP which was preferentially
over-expressed in the cytoplasm and nucleus respectively
(Fig. 3a and b). Over-expression of cytoplasmic cFLIP
was able to protect MCF-7 tumoursphere-forming cells
from TRAIL, whereas over-expression of nuclear cFLIP
was not protective (Fig. 3c). Furthermore overexpression
of cytoplasmic or nuclear cFLIP increased tumoursphere
formation significantly (Fig. 3c), suggesting a role for
cFLIP in bCSC maintenance.
To confirm the effect of cytoplasmic depletion of
cFLIP on TRAIL sensitivity, the CRM1 nuclear trans-
porter inhibitor Leptomycin B (LMB1) was used to se-
quester cFLIP in the nucleus [24]. Twenty-four hour
treatment with 0.1 ng/ml LMB1 reduced cytoplasmic,
and elevated nuclear cFLIP levels in the MCF-7 cell line
(Fig. 3d and Additional file 1: Figure S3A). Pre-
treatment with LMB1 sensitised MCF-7 cells to TRAIL
but this result was not statistically significant (Fig. 3e).
However, pre-treatment with LMB1 significantly en-
hanced the sensitivity of tumoursphere-forming MCF-7
cells to TRAIL (Fig. 3f and Additional file 1: Figure
S3B). This was also the case in the TRAIL-resistant
tumoursphere-forming cells of the SKBR3 and BT474
lines (Additional file 1: Figure S3C and D).
These data show that only cytoplasmic cFLIP can pro-
tect against TRAIL whereas nuclear cFLIP cannot, and
suggest that re-localisation of cFLIP from the cytoplas-
mic compartment to the nucleus can sensitise
tumoursphere-forming populations to TRAIL.
cFLIP promotes the canonical Wnt pathway
cFLIP is well-characterised as an inhibitor of the extrin-
sic apoptosis pathway, a function which requires its
availability in the death inducing signalling complex
within the cytoplasm [7], however the nuclear function
of cFLIP in breast cancer cells is not known. In lung car-
cinoma cell lines cFLIP promotes Wnt signalling by two
separate mechanisms: firstly by preventing the ubiquity-
lation and consequent degradation of beta-catenin in the
cytoplasm, and also by forming a complex with tran-
scription factors in the nucleus to directly promote
Wnt-target gene expression [24, 32, 33].
To investigate whether cFLIP was capable of regulat-
ing the Wnt pathway in breast cancer cells, the protein
levels of beta-catenin were determined following cFLIP
inhibition by siRNA in TRAIL-sensitive MDA-MB-231
and TRAIL-resistant MCF-7 cells. Following 48 h
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transfection, cytoplasmic proteins were analysed for
cFLIP and beta-catenin levels by western blotting. Inhib-
ition of cFLIP resulted in a significant decrease in cyto-
plasmic beta-catenin in both cell lines (Fig. 4a) and this
was confirmed by immunofluorescence in MDA-MB-
231 cells where a decrease in both membrane-bound
and cytoplasmic beta-catenin was observed (Fig. 4b).
The cFLIP-mediated regulation of beta-catenin levels
also correlated with decreased expression of the Wnt-
target gene Axin2 in Wnt3a-stimulated cells [34]
(Fig. 4c). Furthermore in Wnt3a-stimulated cells, the
Wnt-responsive TOPFlash reporter was activated follow-
ing over-expression of nuclear but not cytoplasmic
cFLIP (Fig. 4d). Taken together these data suggest that
cFLIP is a positive regulator of the Wnt pathway and
that nuclear but not cytoplasmic cFLIP augments Wnt
signalling in MCF-7 and MDA-MB-231 cells.
Discussion
We have shown that TRAIL is able to suppress the
clonal expansion of all six breast cancer cell lines tested,
irrespective of their overall sensitivity to TRAIL, and fur-
thermore that TRAIL is able to target directly the stem-
like sub-populations in four of these cell lines. Our find-
ings are in accordance with a recent study which showed
that bCSCs from basal-like breast cancer cell lines were
sensitive to the TRAIL DR5 receptor agonist TRA8 [35].
However this study was limited to only basal-like breast
cancer cell lines which are known to be TRAIL-sensitive.
We show here that not only the bCSC populations of
mesenchymal-like cell lines, but those of the otherwise
TRAIL-resistant epithelial-like MDA-MB-468 and MCF-
7 lines are also TRAIL-sensitive. These data are import-
ant because they widen the range of breast cancer sub-
types for which TRAIL can be considered a potential
Fig. 3 Cytoplasmic but not nuclear cFLIP protects against TRAIL-mediated cell death (a) Western blots for cFLIP performed on cytoplasmic and
nuclear protein extracts of MCF-7 s transfected with overexpression constructs; mock (M, empty vector control), cytoplasmic-localised cFLIP (C)
and nuclear-localised cFLIP (N) (loading controls = α-tubulin and lamin A/C) (b) Densitometry analysis of Western blots for cFLIP performed on
cytoplasmic and nuclear protein extracts of MCF-7 s expressing mutant cFLIP. Data is average of 3 independent protein samples normalised to
Mock control. (c) Tumoursphere Assay of MCF-7 cells stably transfected with either mock, cytoplasmic-localised cFLIP or nuclear-localised cFLIP in
the presence (T) or absence (−) of 20 ng/ml TRAIL. The percentage of tumourspheres is shown relative to the number of cells seeded (d)
Immunofluorescence of MCF-7 cells cultured in the presence or absence of 0.1 ng/ml leptomycin-B (LMB1) for 24 h (cFLIP = grey, DAPI = red) (e)
Cell Titre Blue Assay of MCF-7 cells cultured for 24 h in the presence or absence of 0.1 ng/ml LMB1 before 18 h treatment with 20 ng/ml TRAIL.
Cell viability is shown as relative to the untreated control. (f) Tumoursphere Assay in the presence (T) or absence (−) of 20 ng/ml TRAIL, of MCF-7
cells cultured in adherent conditions for 24 h in the presence or absence of 0.1 ng/ml LMB1. The percentage of tumourspheres is shown relative
to the number of cells seeded. (*p < 0.05, paired t-test, error bars = SEM; all graphs represent means of at least 3 independent experiments)
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therapeutic and also suggest that conventional assays of
cell viability and tumour regression may be insufficient
to assess TRAIL efficacy. Liu et al. has shown recently
that there exist two stem-like populations; EMT-like and
MET-like bCSCs distinguishable on the basis of CD44+
and ALDH+ expression respectively [22]. We show here
that TRAIL targets primarily the CD44+, EMT-like sub-
population of bCSCs in the MCF-7 line. We would pre-
dict therefore that cell lines such as SKBR3, which is
almost 100 % ALDH-positive [36], would be refractory
to killing. The data presented in Fig. 1 supports this
hypothesis.
Recently it has been reported that MCF-7 cells
which had been cultured as 3D tumour spheroids,
then disaggregated and seeded in adherent culture
were more resistant to TRAIL than their non-
spheroid counterparts. Here we have shown that it is
the sphere-forming and tumour-initiating MCF-7 cells
and their early progenitors specifically that are
TRAIL-sensitive. Combined these data suggest that it
is the early stem/progenitors themselves, rather than
their presence in 3D organoids, that determine
TRAIL-sensitivity [37].
We have established one mechanism by which breast
cancer cells including bCSCs are rendered TRAIL-
sensitive. We have shown that TRAIL sensitivity corre-
lates with reduced cytoplasmic localisation of the en-
dogenous TRAIL pathway inhibitor cFLIP. Cytoplasmic
cFLIP levels were particularly low in anoikis-resistant cells
which may explain why the combination of cFLIP inhib-
ition and TRAIL treatment results in the complete abla-
tion of bCSCs, and also why it is more effective for bCSCs
than the bulk population as siRNA-mediated inhibition of
cFLIP would be more efficient in these cases [23].
A number of mechanisms of TRAIL-sensitivity have
been described previously in an attempt to explain dif-
ferences in susceptibility between cancer cells, including
differential expression of death receptors DR4 and 5, re-
ceptor glycosylation or internalisation, and receptor mu-
tations [38–40]. Interestingly, a recent study has shown
that mis-localisation of death receptors can induce
TRAIL-sensitivity; however this study revealed that
TRAIL-receptor expression or localisation did not cor-
relate with sensitivity across a panel of ten breast cancer
cell lines, nor was the TRAIL-susceptibility of stem-like
populations addressed. The authors postulated that
Fig. 4 Nuclear cFLIP promotes Wnt-signalling (a) Western blotting for cFLIP and beta-catenin performed on cytoplasmic protein extracts of MCF-7 and
MDA-MB-231 cell lines transfected with siRNA targeting cFLIP or a scrambled control (loading control alpha-tubulin) (b) Immunofluorescence for cFLIP
and beta catenin of MDA-MB-231 cells transfected with siRNA targeting cFLIP or a scrambled control (red = cFLIP, green = beta catenin, blue = DAPI)
(c) qPCR analysis for mRNA levels of cFLIP and Axin2 in MCF-7 and MDA-MB-231 cells transfected with siRNA targeting cFLIP or a scrambled control
and cultured in the presence of 10 ng/ml Wnt3a for 48 h. Gene expression is expressed as relative to the untreated control. (d) TOPFlash luciferase
reporter assay of MCF-7 cells transfected with overexpression constructs; mock (empty), cytoplasmic-localised cFLIP and nuclear-localised cFLIP and cul-
tured in the presence of 10 ng/ml Wnt3a for 48 h. Luciferase output is expressed as relative to that of the mock-transfected cells. (*p < 0.05, paired t-
test, error bars = SEM; all graphs represent means of at least 3 independent experiments)
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downstream events instead may be responsible for deter-
mination of sensitivity [41]. In terms of regulation of
TRAIL-response by cFLIP, its ability to re-localise DISC
components away from lipid rafts has been shown to
impact on TRAIL-sensitivity of lung carcinoma cell lines
[42]. More recently, hyperthermia-induced aggregation
and re-distribution of cFLIP from the cytosol to the in-
soluble cellular fraction further sensitised the MDA-MB-
231 line to TRAIL [43]. Whether any of these molecular
mechanisms contribute directly to the subcellular redis-
tribution of cFLIP observed in our study remains to be
determined.
We also show here that over-expression of nuclear
cFLIP, in contrast to cytoplasmic cFLIP is not able to
inhibit TRAIL-mediated apoptosis. However we show
that nuclear accumulation of cFLIP promotes the
Wnt-signalling pathway in breast cancer cell lines.
Using the MCF-7 and MDA-MB-231 lines as models
of epithelial-like and mesenchymal-like lines respect-
ively we established that inhibition of cFLIP reduced
beta-catenin levels and Wnt-target gene expression,
whereas over-expression of nuclear cFLIP promoted
Wnt-target gene expression. These data are in accord-
ance with previous studies which show that cFLIP
promotes Wnt signalling in lung carcinoma cell lines
[24, 32, 33] suggesting that cFLIP regulates the Wnt
pathway in the same manner in both lung and breast
cancer cell lines.
As TRAIL alone does not completely eradicate
tumoursphere-forming or tumour-initiating cells in any
breast cancer cell line, we believe our data are evidence
of heterogeneity existing in terms of susceptibility
to TRAIL. We propose a model to explain the
heterogeneous responses of breast cancer cells, includ-
ing bCSCs, to TRAIL (Fig. 5). In this model, epithelial-
like cells (which have reduced levels of Wnt signalling)
have abundant cytoplasmic cFLIP and consequently are
resistant to TRAIL-mediated apoptosis. In contrast,
mesenchymal-like cells have comparatively reduced cyto-
plasmic cFLIP and elevated nuclear cFLIP associated with
its role in the relatively more active Wnt pathway, and are
consequently TRAIL-sensitive. Suppression of cFLIP
levels therefore has the dual beneficial effects of both sen-
sitizing cells to TRAIL and down-regulating Wnt-
signalling (Fig. 5). A down-regulation of Wnt signalling
has the added potential to impact negatively on the main-
tenance of bCSCs [30, 44].
The scope of breast cancer subtypes in vivo which
have TRAIL-sensitive bCSCs has yet to be determined.
An analysis of cFLIP and TRAIL sensitivity of primary
ex vivo tumourspheres in a large panel of tumour sam-
ples would help to establish whether such direct correla-
tions exist. Our data suggest that subcellular localisation
of cFLIP as opposed to absolute levels may predict re-
sponse to TRAIL in bCSCs. This means that its efficacy
as a biomarker of bCSC response is limited as conven-
tional IHC of pathological sections would not be able to
identify the minority bCSC subpopulation. The clinical
implication of our findings are that although TRAIL
alone is a potential therapy which requires unconven-
tional methods to determine tumour efficacy, a much
more effective therapeutic strategy would be to also in-
hibit cFLIP (Fig. 5), the consequences of which would
not just be a sensitisation to TRAIL but also a reduction
in Wnt signalling and therefore potentially a reduction
in bCSC self-renewal and proliferation.
Fig. 5 Proposed Model of TRAIL-Susceptiblity in Breast Tumour Subpopulations: (a) Epithelial-like cells have cytoplasmic cFLIP and consequently
are resistant to TRAIL-mediated apoptosis. (b) Mesenchymal-like cells have comparatively reduced cytoplasmic cFLIP and elevated nuclear cFLIP
due to its role in the relatively more active Wnt pathway, and are consequently TRAIL sensitive (c) The consequences of cFLIP inhibition:
sensitisation to TRAIL, reduction in Wnt signalling and potentially a reduction in bCSC self-renewal and proliferation
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Conclusions
In conclusion we have shown that a safe and available
therapeutic agent is able to target the stem-like popula-
tion of six breast cancer cell lines. Sensitivity to TRAIL
was mediated by the cytoplasmic levels of the apoptosis
inhibitor cFLIP. Our findings suggest a potential for
TRAIL in the treatment of breast cancer patients. Fur-
ther investigation is required to determine the TRAIL-
susceptibility of clinical samples ex vivo.
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